FindTrial
Sign In

Weekly Paclitaxel

DRUG5 trials

Sponsors

Instituto do Cancer do Estado de São Paulo, Seoul National University Hospital, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Yonsei University, NSABP Foundation Inc

Conditions

Breast CancerEpithelial Ovarian CarcinomaFallopian Tube CarcinomaHER-2 Positive Breast CancerHER2-negative Breast CancerOvarian CancerOvarian NeoplasmsPrimary Peritoneal Carcinoma

Phase 1

A Trial of Weekly Paclitaxel With Oncothermia and Weekly cisPlatin With Oncothermia in Patients With Recurrent or Persistent Ovarian Cancer
CompletedNCT02344095
Seoul National University HospitalEpithelial Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
Start: 2014-12-31End: 2017-10-31Updated: 2024-07-12

Phase 2

Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling
NCT03412643
NSABP Foundation IncHER2-negative Breast Cancer
Start: 2018-05-14End: 2023-10-30Target: 64Updated: 2023-03-06

Phase 3

Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients
CompletedNCT02903004
Fondazione Policlinico Universitario Agostino Gemelli IRCCSOvarian Neoplasms
Start: 2016-04-11End: 2018-12-20Updated: 2021-08-25

Unknown Phase

Chemotherapy for Elderly Patients Diagnosed With Localized HER2 Positive Breast Cancer
WithdrawnNCT02102438
Instituto do Cancer do Estado de São PauloBreast Cancer, HER-2 Positive Breast Cancer
Start: 2014-04-30End: 2018-04-30Updated: 2016-08-31
Real-World Effectiveness of Bevacizumab Based on AURELIA in Platinum-resistant Recurrent Ovarian Cancer
CompletedNCT03367182
Yonsei UniversityOvarian Cancer
Start: 2017-09-01End: 2018-01-31Updated: 2019-01-11

Related Papers

INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line.
2023-02-0920 citations
Modulated electro‑hyperthermia with weekly paclitaxel or cisplatin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: The KGOG 3030 trial
Experimental and Therapeutic Medicine2021-05-213 citations
A phase I trial evaluating the safety and efficacy of weekly paclitaxel or cisplatin with electro-hyperthermia in patients with recurrent or persistent epithelial ovarian, fallopian tubal or primary peritoneal carcinoma (KGOG 3030).
Journal of Clinical Oncology2019-05-20
Real-world effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA): A Korean Gynecologic Oncology Group study (KGOG 3041).
2018-11-0619 citations